BioSpace News Archive

Kyverna Therapeutics today announced the filing of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for KYV-101, a novel therapy for the treatment of lupus nephritis.

Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib, announced the addition of eminent cancer research leaders Roger B. Cohen, MD, Lee M. Ellis, MD, and John L. Marshall, MD to their Scientific Advisory Board.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it will share two poster presentations, namely the Phase 2 AURELIO-04study design of the IL-15 superagonist, SOT101as a Trial in Progress and nonclinical data on mechanism of action of its BOXR T cell platform at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its third quarter 2022 financial results on Monday, October 31, 2022, after the market closes.

Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced favorable results from its recently completed SEQURUS-2 study.

ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York, New York.

Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, announced today the granting of a patent by the U.S. Patent and Trademark Office.

IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”), a leader in pharmaceutical films, today announced that it has responded to the Complete Response Letter (“CRL”) for its 505(b)(2) New Drug Application (NDA) for RIZAPORT® VersaFilm® received from the U.S. Food and Drug Administration (“FDA”) in March 2020.

Today, real world evidence (RWE) leader Target RWE announced a partnership with the American Association for the Study of Liver Diseases (AASLD) to support its Cirrhosis Quality Collaborative (CQC), effective immediately.

Heska Corporation, a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its third quarter 2022 financial performance in a press release before the market opens on Tuesday, November 8, 2022.